Brefeldin A

Catalog No.S7046

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Price Stock Quantity  
USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Brefeldin A  Chemical Structure

Brefeldin A Chemical Structure
Molecular Weight: 280.36

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare ATPase Inhibitors
    Compare ATPase Products
  • Research Area

Product Description

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets ATPase (HCT 116) [1]
IC50 0.2 μM
In vitro Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
PC12NFnQZmdHfW6ldHnvckBCe3OjeR?=MkPONkDPxE1?NGK1PZYyKGh?NFj3[3pqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA>NX\CUZlnOjZ|NkOxPVE>
C2C12NVLjbHVLTnWwY4Tpc44hSXO|YYm=MWexxsDPxGdxbXy=MXqxxsBpNYi2[5BZ[WKxbHnzbIV{KGO7dH;rbY5mKHKnbHXhd4Uh\nKxbTDDNmMyOiCveX;0eYJmew>?NWT4S5lFOjZ{OUGyO|k>
MEFs WTNYrxbodTTnWwY4Tpc44hSXO|YYm=NV\BTXI3PcLizszNNUW5OHlbOjBibXnuM2frTYNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ?MmXoNlYyQTZyMkO=
MEFs VAMP7 KONHrGdZJHfW6ldHnvckBCe3OjeR?=MYO1xsDPxE1?MVSyNEBucW5?NYfDUZF1[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?=NHG1b3MzPjF7NkCyNy=>
SMCsMW\GeY5kfGmxbjDBd5NigQ>?NYPKPJVMOTEEoNM1[{9udA>?NYS3bnlsOC1zMjDoMk[xSG1UVw>?M4nEbZNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA>NYTFTYlNOjZzN{KwPFA>
SMCsMlfwSpVv[3Srb36gRZN{[Xl?MUWxNOKhyrWpL33sMn7yNE0yOiCqMYnEUXNQNWfwfZN3[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?=NVHRUpZmOjZzN{KwPFA>
HEMC-1MmfpSpVv[3Srb36gRZN{[Xl?M1G0NFAvOcLiwsXnM41tNXvud3h5OjUEoHi=Mm\5Z4F2e2W|IHGgbIlocGW{IHnubIljcXSxcomg[YZn\WO2IH;uJIV5d2O7dH;zbZMhfGijbjDuc4Nw\GG8b3zlNGiySYYzPTl5Mke1PS=>
HUVECMl75SpVv[3Srb36gRZN{[Xl?NGXrVIkyOMLizszNM2XafVHDqGh?NGXteJlFVVORM4fS[IFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W|M3LUeFI2QTV4OUi4
HUVECNXHjS|V6TnWwY4Tpc44hSXO|YYm=MnnBNVDDqM7:TR?=NVryOGpvOcLiaB?=Mo\PSG1UVw>?NIjteG1qdmO{ZXHz[ZPDqHSqZTDueY1j\XJiYX7kJIlvfGWwc3n0fUBw\iCobIXvdoV{[2WwdDDhdoVieyCnc4DlZ4lidGy7IHnuJJBmemmwdXPs[YFzKHOyYXPlM17JfFI2QTV4OUi4
Caco-2Mn7LSpVv[3Srb36gRZN{[Xl?NEDNWXkzNjVizszNNGiy[Xo{OCCvaX6=NUXlVXpZ[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:wNFvyT2YzPTl3NEmzNS=>
NRKM17nb2Z2dmO2aX;uJGF{e2G7M{LsT|IxOOLChX7nM41tM1\0TlTjiIWqMonXSG1UVw>?MUXy[ZNkfWW|IH3peI91cWNicILv[5Jme3Orb36=NIixUXUzPTl2OEW4Oi=>
HeLaNWrtZXZ4TnWwY4Tpc44hSXO|YYm=MVeyNFDjiIWwZz;tcC=>NF\qdZE{KGh?MmLZSG1UVw>?MnnnbY5lfWOnczD0bIUh[XK2aX\pZ4lidCCkcnXhb{12eCCxZjD0bIUhT2:uZ3mgZ49ueGyneB?=MVWyOVk1QDV6Nh?=
COSM1yyUWZ2dmO2aX;uJGF{e2G7M1HrR|Eh|rypL33sNYPjU5d{OyCqM4HFPYNwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKhMmfWNlU6OTV7MEC=
DF1 M1:zVmZ2dmO2aX;uJGF{e2G7NXPMV4dxOcLizszNxsA>MYS0PEBpMoWxSG1UVw>?Mnn6[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?=MmPwNlU5ODdyNUS=
nHDFs M{TCT2Z2dmO2aX;uJGF{e2G7MW[xxsDPxE4EoB?=NYXPTplLOsLiaB?=MXjwdoV3\W62czD0bIUh[XO|ZX3icJkhd2ZiY4n0c5NwdGmlIHPvZZQheHKxdHXpcpMhd262bzDHc4xocSCvZX3idoFv\XN?M1HmTVI2Pzd{NkG2
FRT MU\GeY5kfGmxbjDBd5NigQ>?NUjXWno1PSEQvHevcYw>NGizbVUzyqCqMWficI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?=M4PhVVI2PzZ5MUG1
FRT NYnUNFg3TnWwY4Tpc44hSXO|YYm=MWO1JO69\y:vbB?=MoSyNuKhcA>?MmTJdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2WmNEi1UXczPTd4N{GxOS=>
HepG2 NGm1[41HfW6ldHnvckBCe3OjeR?=MnTZNgKBkcL3TdMgM2fRNVI1KGh?MWTEUXNQMWPk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKFC[UjDtVm5CNYfXU4NqOjV4MU[1PVc>
SMCsM1ftUmZ2dmO2aX;uJGF{e2G7NYXMOZdSOc7:Zz;tUC=>NXroPHl1OyCqMorrZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC=NILwPIwzPTV6OUSyOS=>
OB-6MUDBdI9xfG:|aYOgRZN{[Xl?M4nXOlIvP8LizszNNWTQbYdvPDhiaB?=M{Tnb4lv\HWlZYOgZZBweHSxc3nzNUX2TVZZOjV3M{K0PFA>
iPSC-CMs Ml3ISpVv[3Srb36gRZN{[Xl?NHXVemQ2ODBibnevcYw>MXW0PEBpMY\pcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjD0bIUhcGmpaHXyJI1w[mmuaYT5JGxCVVC|IHH0JJRp\SClb4P0JI9nKHSqZTDsc5dmeiCvb3LpcIl1gSC|cHXjbYV{MUeyOVQ5QDZ4Nh?=
SP-NlucNFf6[mhHfW6ldHnvckBCe3OjeR?=M1HHUlUhdWdxbVy=Ml\NOkBpMojOSG1UV8LiMUHjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTlNYDwTlhKOjV|OUK5PVg>
PEXEL-NlucMV7GeY5kfGmxbjDBd5NigQ>?M4fXd|UhdWdxbVy=NWPqWIQxPiCqMYLEUXNQyqB?MkLFZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=>MXqyOVM6Ojl7OB?=
H1299M2fQNGZ2dmO2aX;uJGF{e2G7MY[xNEDPxGdxbXy=MXSyOEBpMonqbY5lfWOnczDheZRweGijZ4pCpC=>M{HrOVI2Ozh6OUew
MDA-MB-231MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>MXyw5qCUPTBizsznM41NMV20PEBpNGrxUIVGSzVywrC9JFAvODF4INM1[{9uVA>?NXzDWWFHOjV|NU[1Olc>
MDA-MB-231MWnBdI9xfG:|aYOgRZN{[Xl?NH[zfmkxNjFizsznM41NMUC0JIg>NGKzWppqdmS3Y3XzJIFxd3C2b4Ppdy=>NV7lcodqOjV|NU[1Olc>
MDA-MB-231MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;OUpAxNjBzL{CuNFUh|rypL33MM2HKdVI1KGh?MX7pcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIIP1Zk1IOSClZXzsJIRm[nKrcx?=NX7aT2V{OjV|NU[1Olc>
MDA-MB-231MluwRZBweHSxc3nzJGF{e2G7NYq3S25jOC5yNfMAl|Eh|rypL33MNGfjbIkzPCCqMmjnbY5lfWOnczDQRXJRKCiyb3z5JGFFWC2{aXLvd4UheG:ueX3ldoF{\S1zKTDjcIVifmGpZR?=M3fOU|I2OzV4NU[3
MDA-MB-231Mn\XSpVv[3Srb36gRZN{[Xl?NH2zcY4x6oDVNUCg{txoN22OMVGyOEBpMkHJbY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO=Mnv4NlU{PTZ3Nke=
A172NInWO|ZHfW6ldHnvckBCe3OjeR?=NF7qT|EyOMLizsznM41tM2Dz[FTDqGh?MXrEUXNQyqB?MVTy[ZN2dHS|IHnuJJRp\SC{ZYTyc4dz[WSnIITyZY5{eG:{dDDv[kBndHWxcnXzZ4VvfCCpcnHueYxmew>?M2qwbVI2OjN7NUC3
KMS-6MoPTSpVv[3Srb36gRZN{[Xl?Mo\qNeKh|ryPwrC=MkG4NlQhcA>?NIPoc5dmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y=MWCyOVIzQTF{Nh?=
MECMnTISpVv[3Srb36gRZN{[Xl?MXexJO69VQ>?MXyxMlUhcA>?MYTjZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI>Mn74NlUzOjh6MUW=
HEK293/hERGMmTNSpVv[3Srb36gRZN{[Xl?M1;HeFExyqEQvF2=MYKxxsBpM3nVfZJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLiNEXNfFYzPTJzOES2PS=>
RBE4NU[wdIk1SXCxcITvd4l{KEG|c3H5NIf6WWYzyqEQvF2=Mk\vN-KBmzJ2wrDoMUTpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7MVeyOVEzQDB{NR?=
RBE4M{G4WmZ2dmO2aX;uJGF{e2G7NH;OZ4kzyqEQvF2=MmnGN-KBmzJ2wrDoM{fhU4lv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=>MWGyOVEzQDB{NR?=
RBE4MUnGeY5kfGmxbjDBd5NigQ>?M1zYTVLDqM7:TR?=NFq5RYE{6oDVMkVCpIg>MYLpcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=>MWKyOVEzQDB{NR?=
RBE4Mn3rSpVv[3Srb36gRZN{[Xl?MUGyxsDPxE1?M2XlTlPjiJN{NNMgbC=>Mlq4bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUl;TJJRqdWVvZHXw[Y5l\W62bIm=NYf2[HA2OjVzMkiwNlU>
RBE4M1qyOWZ2dmO2aX;uJGF{e2G7MYmyxsDPxE1?MVGz5qCUOjUEoHi=NIDVelNqdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm=Mn7nNlUyOjhyMkW=
RBE4MnvaSpVv[3Srb36gRZN{[Xl?NIK0UYQzyqEQvF2=NGHVW3c{6oDVMkVCpIg>MWnpcoR2[2W|IHHuJI93\XKub3HkJI9nKEOjMjxCpIlvKHSqZTDtbZRw[2ixbnTybYEhcW5idHjlJIZqenO2IEdCpIghd2ZiaX7jeYJifGmxbjCodQKBkT{kgJmwMlAxOSliYoX0JGNiOiwEoHzleoVteyCrbjD0bIl{KG:{Z3Hu[Yxt\SCmZXPy[YF{\WRiYX\0[ZIhOTMEoHigc4YhcW6ldXLheIlwdg>?Ml7ONlUyOjhyMkW=
Huh-7 M4C0e2Z2dmO2aX;uJGF{e2G7NXXYUGxHOc7:Zz;tUC=>NYCxbHNrO+LCk{K0xsBpMkLRbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyM2TtblI2ODJ4MUe0
HepG2 MVnGeY5kfGmxbjDBd5NigQ>?NV;n[IRDOc7:Zz;tUC=>NWfvOnh{O+LCk{K0xsBpMlfrbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyMWKyOVAzPjF5NB?=
H838-LKB1Mlq2SpVv[3Srb36gRZN{[Xl?M2\sOFMxyqCwZz;tcC=>M2jZdVEzNzF6IHi=MkGybY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=>MlWzNlUxOTFyOEK=
H838-KDLKB1 NGG0c5dHfW6ldHnvckBCe3OjeR?=M1KyRVMxyqCwZz;tcC=>M1vQOlEzNzF6IHi=NHXzcmtqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKhNHXhcIwzPTBzMUC4Ni=>
H838-KDLKB1 NWfoUZg2TnWwY4Tpc44hSXO|YYm=MnjHN|DDqG6pL33sNHHodpMyOi9zODDoMlT1bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm=NGnWTIszPTBzMUC4Ni=>
3T3-L1NHrLVHFHfW6ldHnvckBCe3OjeR?=MYm1JO69\y:vbB?=MkLFN|AhdWmwNE[4c2NucW2rY4OgeIhmKGWoZnXjeJMhd2ZiaX7zeYxqdiCjbnSgZ4F2e2W|IILvZpV{fCCyaH;zdIhwenmuYYTpc44hd2ZiQXv0JEhU\XJiNEezLUBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIFHTNVYxKCiWaIKgOlQzKGGwZDDT[ZIhPTh6KR?=MoPpNlQ5PDN6Mke=
3T3-L1M3nC[WZ2dmO2aX;uJGF{e2G7MVO1JO69\y:vbB?=M4S5fFMxKG2rbh?=NEPvVI1z\WOjcHn0eYxifGW|IHnud5VtcW5iYXP0bY9vKHerdHigdoV{eGWldDD0c{Bz\We3bHH0bY5oKEGtdDDhZ5Rqfmm2eTDhcoQhSVNzNkCgdIhwe3Cqb4L5cIF1cW:wNVfxdnZPOjR6NEO4Nlc>
3T3-L1M3;kTWZ2dmO2aX;uJGF{e2G7MnHGOUDPxGdxbXy=NWXSU3RvOzBibXnuNX3wXJpK[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES=M1nSVVI1QDR|OEK3
3T3-L1NX\iRmdGTnWwY4Tpc44hSXO|YYm=MYm1JO69\y:vbB?=MWmxxsBpMXnjZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=>NV;kSGdpOjR6NEO4Nlc>
3T3-L1M2rt[2Z2dmO2aX;uJGF{e2G7M3OxTlUh|rypL33sM{[wXVHDqGh?MVfjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=>NF\1OoUzPDh2M{iyOy=>
HeLa NVqz[|dRTnWwY4Tpc44hSXO|YYm=M4juUlUh|rypL33sNHfIbZY{KGh?NETGXW1k[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN?MkO4NlQ5PDN6Mke=
HEK293NIPtTolHfW6ldHnvckBCe3OjeR?=M3W2O|XDqM7:Zz;tcC=>NYruflNxOTMEoHi=NWXOWG1x[WKxbHnzbIV{KEOPQT3pcoR2[2WmIFPSSWxFOiC|ZXPy[ZRqd25?NF;OPWYzPDZ6N{SzNS=>
COS-1M3TmdmZ2dmO2aX;uJGF{e2G7NGTjXYs2KML3Zz;tcC=>NUTLTYZEOjRiaNMgNGP6cpBz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>?MYmyOFY4OTd3MR?=
PRPNELEXHFHfW6ldHnvckBCe3OjeR?=NFrsXo4yOCEQvF2=MU\hZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>?NXHTVmZIOjR4Nki3OVA>
RAW264.7M2q5VWFxd3C2b4Ppd{BCe3OjeR?=M4XsW|Qh|ryPMnvVOFghcA>?NFvrS5lifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?=NV3CcHZYOjR4M{mwN|I>
MDMsNHS5OpNCeG:ydH;zbZMhSXO|YYm=MYWxNQKBkc7:Zz;tcC=>NWrYbpU4OTJxMUWgbC=>M1jPb4lv\HWlZYOgZZBweHSxc3nzNHT1UY4zPDV3Nk[5OS=>
PMHs MUPGeY5kfGmxbjDBd5NigQ>?MWWxNQKBmzJy4pEJ{txoN22uM2fWdVI16oDLaB?=NYHNSItOTE2VTx?=NH;wN3VqdmS3Y3XkJGVTKHO2cnXzdy=>NVTSVG9YOjR2MEeyOFI>
PMHs M3nPZWFxd3C2b4Ppd{BCe3OjeR?=NFPibm0yOOLCk{Kw5qCK|rypL33sNYjFOFJnOjUkgJnoMnSxSG1UVw>?Mo\MbY5kemWjc3XzJINmdGxiZHXheIg>M3;zdFI1PDB5MkSy
HEK293/tauNFG0ZpVHfW6ldHnvckBCe3OjeR?=Mo\XOUDPxE1?NIfadXYyNzJxNDDoMojxbY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA>MYmyOFM3QDB6OR?=
HEK293/tauM1vrcGZ2dmO2aX;uJGF{e2G7MXW1JO69VQ>?MoDVN{BpMXvpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>?NYKw[HUyOjR|NkiwPFk>
ADFNXLHdGtUTnWwY4Tpc44hSXO|YYm=M{W3elExKM7:TR?=M2T4U|E3KGh?M{\u[4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JVMYKyOFIzQDJ|Mh?=
U373 MV\GeY5kfGmxbjDBd5NigQ>?NUHkPWtJOTBizszNMk\mNVYhcA>?M3zIWolvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JVNFf4UlIzPDJ{OEKzNi=>
RKO-HIPK2iM{O1N2Z2dmO2aX;uJGF{e2G7NULkVoUyOTBizszNM4LmVFE3KGh?MVnpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=>MoPjNlQzOjh{M{K=
ADF NVzTOIo{TnWwY4Tpc44hSXO|YYm=M2PIb|ExKM7:TdMgNW\Yd25QPiCqMlj1bY1x[Wm{czD0bIUhTENiYXP0bZZifGmxbh?=MkLmNlQzOjh{M{K=
Huh7MWPGeY5kfGmxbjDBd5NigQ>?NHLvTHQ2KM7:Zz;tcC=>MVq0JIg>NV3rSndU[WKxbHnzbIV{KHSqZTDz[YNz\XSrb36gc4YhKGmwdILhZ4VtdHWuYYKgRZBwSg>?MkLlNlQyODBzNEC=
Huh7NETFVoJHfW6ldHnvckBCe3OjeR?=NYO2c5BLPSEQvHevcYw>MV[xJIg>NETEWVNk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>?M17OR|I1OTByMUSw
Huh7NGrjTYtHfW6ldHnvckBCe3OjeR?=NYP3XWFFPeLCk{GwxsBv\y:vbB?=NHS5cHoyOiCqNXnIOJpRcW6lcnXhd4V{KEGyb1KtZ5Jme2OnboTzJJdqfGixdYSgbY5pcWKrdHnu[{B{\WO{ZYTpc44>MmXYNlQyODBzNEC=
BAECsM1jTTmZ2dmO2aX;uJGF{e2G7NF3vXmE2KM7:Zz;tcC=>NG\He20xNTRiaB?=NHTDdZJqdmS3Y3XzJJRp\SC{YYDp[EBl\XCqb4PwbI9zgWyjdHnvckBw\iCnTl;TJIF1KFOnckGxO|k>MVOyOFA5PTJ{NR?=
MacrophagesNFf0NJZHfW6ldHnvckBCe3OjeR?=MoLiO|EhyrWPNH3MSYc3KGh?NYK3Oo9DcW6qaXLpeJMhdHWwYYPpckBqdnSncn7hcIl7[XSrb39CpC=>MoPSNlQxOzl5NEC=
Colo 205NFvMe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV2wMVUh|rypL33MM3mzTVQ5KGh?MojjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?=MVWyN|k4Ozl7Nh?=
Colo 205NIXCdVNHfW6ldHnvckBCe3OjeR?=NGjVUXkxNjBzMj2wMlAzPSEQvHevcWw>NWLHTHhSOTRiZB?=M3\DdJJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?=NWrlSoM4OjN7N{O5PVY>
Colo 205MXvBdI9xfG:|aYOgRZN{[Xl?NEm1OHQxNjFizsznM41NMmPHNE0zPCCqNWrWbph2cW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?=NWe5[ZNQOjN7N{O5PVY>
Colo 205NUX5[I5ITnWwY4Tpc44hSXO|YYm=NG\xblMxNjBzNTFOwIcwdUx?MWmyOEBpM1LCeolv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN?NXLSS|B[OjN7N{O5PVY>
Colo 205NHLHXHdHfW6ldHnvckBCe3OjeR?=MnHFNE4xOTVizsznM41NM4rPXlI1KGh?NYTCe5czcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWHN?MkPNNlM6PzN7OU[=
IBRS2NFn1PW1HfW6ldHnvckBCe3OjeR?=NGrZXmk2KM7:Zz;tcC=>MYqwMlUhcA>?MUPEUXNQMUDkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA>MknqNlM6PjN3M{S=
IBRS2MX7GeY5kfGmxbjDBd5NigQ>?MY[1JO69\y:vbB?=M{j2dFAvPSCqM1vNb2ROW09?MYPlcohidmOnczDGUWRXKGmwZnXjeIlwdg>?MkPENlM6PjN3M{S=
HeLaM1LJUWZ2dmO2aX;uJGF{e2G7NYHVTHNOOiEQvF2=NXrPZ3lOOiCqwrC=NGPTcpdifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU>NGTRSFgzOzl3MEi5Ni=>
HFS NVjoNlhRTnWwY4Tpc44hSXO|YYm=M1jXTFAuOSEQvHevcYw>NGDIfmQzPCCqM13ubGdNXFBiZYjwdoV{e2mxbjDy[YFkcGW|IHGgdIxifGWjdTDheEBkd26lZX70doF1cW:wczDhd{Btd3diYYOgNE4xOSEEtXevcYw>MkXVNlM5QTR4M{O=
HFS MVrGeY5kfGmxbjDBd5NigQ>?MY[wMlAyKML3Zz;tcC=>NFrjPJAzPCCqMnSxbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>?MY[yN|g6PDZ|Mx?=
OVCAR-3M3jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlToNgKBmzF3wrFOwG3DqA>?NUPKdW11OjUEoHi=M3zaPYlv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?=Mkj1NlM5OjZ7NkS=
OVCAR-3Mn3PSpVv[3Srb36gRZN{[Xl?M33DfVHjiJNzNdMg{txOyqB?NV7EVY9jOjUEoHi=MmDFbY5lfWOnczDueYNt\WG{IHThcYFo\Q>?NYPHXW9ROjN6Mk[5OlQ>
OVCAR-3NEnHZY5CeG:ydH;zbZMhSXO|YYm=MmfqNU0yOMLizszNMVO0JIg>MX;pcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6|NWj4fpdSOjN6Mk[5OlQ>
OVCAR-3NWLLT|EySXCxcITvd4l{KEG|c3H5M1jYVlExyqEQvF2=NXrXVmZSOjUEoHi=NGDkZXZqdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN?NHHlTJMzOzh{Nkm2OC=>
OVCAR-3M3G0dWZ2dmO2aX;uJGF{e2G7NXz5XIpVOeLCk{GwxsDPxE1?NXrSRmczOjUEoHi=NEXGUmtqdmS3Y3XzJIRqe3K3cITpc44hd2ZidHjlJI1qfG:laH;u[JJq[WxidILhcpNu\W2kcnHu[UBxd3SnboTpZYw>NV3tWJVXOjN6Mk[5OlQ>
OVCAR-3M1zLZ2Z2dmO2aX;uJGF{e2G7M17nRVHjiJNzMNMg{txOMV2yOOKhcA>?NHj0blJqdmS3Y3XzJIZwem2jdHnvckBw\iC{ZXHjeIl3\SCxeInn[Y4he3CnY3nldy=>M1LPeFI{QDJ4OU[0
OVCAR-3NITIT25HfW6ldHnvckBCe3OjeR?=MYmx5qCUOTEEoN88US=>Ml3TNlTDqGh?M2PiNYlvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=>MojvNlM5OjZ7NkS=
MKN45MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH70Xo5KSzVyPECuNFAyKM7:Zz;tcC=>MnrzNlM4QTN|NEK=
LOVOM3:xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PsdWlEPTB;MD6xNkDPxGdxbXy=MWmyN|c6OzN2Mh?=
A549Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfqTo5KSzVyPUCuNFQh|rypL33sMVeyN|c6OzN2Mh?=
MDA-MB-435MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPOW5h3UUN3MEywMlAxOSEQvHevcYw>MmrGNlM4QTN|NEK=
HepG2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrXfVM{UUN3MEywMlAxOSEQvHevcYw>NV65fIRVOjN5OUOzOFI>
HL-60M4C0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;2fXd3UUN3MEywMlAxOSEQvHevcYw>NE\EcY4zOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Cell Assay: [5]

Cell lines Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
Concentrations 0 ng/mL -75 ng/mL
Incubation Time 5 days
Method HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Zhu JW, et al. Bioorg Med Chem. 2000, 8(2), 455-463.

[2] Ohnishi Y, et al. Br J Pharmacol. 2001, 134(1), 168-178.

view more

Chemical Information

Molecular Weight (MW) 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 4 mg/mL (14.26 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4H-Cyclopent[f]oxacyclotridecin-4-one, 1,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, (1R,2E,6S,10E,11aS,13S,14aR)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ATPase Products

  • Elacridar (GF120918)

    Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

  • Verdinexor (KPT-335)

    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

  • Oligomycin A

    Oligomycin A is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

  • (-)-Blebbistatin

    (-)-Blebbistatin is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

  • Omecamtiv mecarbil (CK-1827452)

    Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure. Phase 2.

  • Esomeprazole sodium

    Esomeprazole Sodium is a sodium salt of esomeprazole that is a potent proton pump inhibitor with an IC50 of 0.076 mg/kg.

  • Sodium orthovanadate

    Sodium orthovanadate is an alkaline phosphatase and (Na,K)-ATPase inhibitor with IC50 of 10 μM.

  • Golgicide A

    Golgicide A is a potent and rapidly reversible GBF1 inhibitor.

  • Ciclopirox ethanolamine

    Ciclopirox ethanolamine (Ciclopirox olamine, HOE 296) is a broad-spectrum antifungal agent working as an iron chelator.

    Features:Exhibits antifungal activity via a specific iron limiation mechanism, with no single case of fungal resistance reported.

Recently Viewed Items

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us